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Abstract
Background: During wound repair, fibroblasts orchestrate replacement of the provisional matrix
formed during clotting with tenascin, cellular fibronectin and collagen III. These, in turn, are critical
for migration of endothelial cells, keratinocytes and additional fibroblasts into the wound site.
Fibroblasts are also important in the deposition of collagen I during scar formation. The CXC
chemokine chicken Chemotactic and Angiogenic Factor (cCAF), is highly expressed by fibroblasts
after wounding and during development of the granulation tissue, especially in areas where
extracellular matrix (ECM) is abundant. We hypothesized that cCAF stimulates fibroblasts to
produce these matrix molecules.
Results: Here we show that this chemokine can stimulate precocious deposition of tenascin,
fibronectin and collagen I, but not collagen III. Studies in culture and in vivo show that tenascin
stimulation can also be achieved by the N-terminal 15 aas of the protein and occurs at the level of
gene expression. In contrast, stimulation of fibronectin and collagen I both require the entire
molecule and do not involve changes in gene expression. Fibronectin accumulation appears to be
linked to tenascin production, and collagen I to decreased MMP-1 levels. In addition, cCAF is
chemotactic for fibroblasts and accelerates their migration.
Conclusions: These previously unknown functions for chemokines suggest that cCAF, the chicken
orthologue of human IL-8, enhances healing by rapidly chemoattracting fibroblasts into the wound
site and stimulating them to produce ECM molecules, leading to precocious development of
granulation tissue. This acceleration of the repair process may have important application to healing
of impaired wounds.
Background
Chemokines are small, positively charged, secreted pro-
teins that consist of an N-terminal region of variable con-
formation, three antiparallel beta-pleated sheets
connected by loops, and a C-terminal alpha helix [1].
These proteins are multifunctional, with different regions
of the molecules, in particular the N- and C-termini, per-
forming specific functions [e.g. [1–4]].
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BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/13Chemokines are best known for their functions in attract-
ing and activating leukocytes. Shortly after injury, these
small cytokines are primarily produced by fibroblasts,
chemoattract leukocytes and activate their integrins caus-
ing them to adhere strongly to the endothelial cells as a
prelude to their migration through the blood vessel wall
to the underlying tissue and towards the source of the
chemokine [5]. In addition to these functions during the
early stages of wound healing, these small cytokines are
also known to be involved in re-epithelialization, angio-
genesis and granulation tissue development [3,6–8], proc-
esses that are critical for proper healing.
The first evidence that chemokines are associated with
wound healing in vivo was reported in 1990 using the
chemokine cCAF (chicken Chemotactic and Angiogenic
Factor; the product of the 9E3 gene), a CXC chemokine
that is now known to be the ortologue for human IL-8 [9].
cCAF is expressed to high levels very shortly after wound-
ing and during the first 24–48 hours after injury, and re-
mains elevated for at least 16 days after wounding [6,10].
It is primarily expressed by the fibroblasts of the granula-
tion tissue, especially where interstitial collagen (Coll) is
abundant, but the levels are also high in the endothelial
cells of the microvessels, in the healing epidermis and in
the connective tissue beneath the skin [6,11]. In the chick-
en chorioallantoic membrane (CAM) assay, low concen-
tration of cCAF results in chemotaxis of monocyte/
macrophages and lymphocytes and the formation of a
granulation-like tissue beneath the chemokine-contain-
ing pellet [3]. After four days of exposure to this chemok-
ine, the ectoderm of the CAMs becomes thickened and the
amount of fibrillar collagen in the tissue is markedly in-
creased, strongly suggesting that cCAF is able to initiate
some of the primary events that lead to granulation tissue
formation [3].
Fibroblasts are important cells in the healing process.
Upon injury, they are activated by the cytokines and
growth factors released during the coagulation process to
produce chemokines and additional cytokines and
growth factors that are important in setting up the cascade
of events that lead to granulation tissue formation. Acti-
vated fibroblasts proliferate and migrate across the provi-
sional matrix formed by the fibrin-plasma fibronectin
(FN) clot. As the clot is digested by plasmin, fibroblasts re-
place it with cellular FN, tenascin (TN) and Coll III
[12,13]. These extracellular matrix proteins are critical for
migration of endothelial cells, keratinocytes and addition-
al fibroblasts into the wound and are important for proper
generation of healthy healing tissue. Some of the fibrob-
lasts differentiate into myofibroblasts, which contract to
close the wound [4,14,15]. Myofibroblasts are fibrogenic,
showing elevated expression of interstitial collagens, lam-
inin, FN and TN, and inhibitors of matrix metalloprotein-
ases such as TIMP-1 [15–19]. Because cCAF is expressed
highly in the granulation tissue of wounds in areas where
ECM is abundant [3,6,11], and it stimulates fibroblasts to
differentiate into myofibroblasts [4], we investigated
whether this chemokine stimulates the production of the
four major ECM molecules mentioned above, interstitial
Colls I and III, TN and cellular FN. Here we show that
cCAF stimulates cultures of fibroblasts to produce TN, FN,
and Coll I, albeit with different dynamics and that these
ECM molecules are also increased in wounded tissues
treated with cCAF.
Results
To mimic the wound environment, we used primary em-
bryonic fibroblasts cultured under very low serum condi-
tions. Unlike adult primary fibroblasts, these cells have
many of the properties of wound fibroblasts. They are able
to proliferate rapidly, to synthesize tenascin and other
non-collagen extracellular matrix molecules, and they
have the ability to differentiate into myofibroblasts [4,20]
that are characteristically found in the granulation tissue
of wounds. The presence of small amounts of serum in the
culture medium mimics the conditions of the healing
adult wounds, where serum factors are more abundant
than in normal tissue. When exposed to these factors, em-
bryonic wounds heal in the same manner, with scarring,
as adult wounds do [21,22].
We used primary cell cultures because cells that are pas-
saged many times can acquire genomic changes, lose their
differentiated phenotype and display altered ECM expres-
sion [23]. However, because the cells are derived from dif-
ferent embryos, there are variations in the levels of cellular
responses reflecting the genetic variation present in vivo.
Therefore, we always include internal controls and do not
average results from different batches of cells; in each fig-
ure, data are from one representative experiment. For the
studies in vivo, the results shown are all from the same ex-
periment so that correlations can be made between the
immunolabeling and immunoblot analysis for each ECM
molecule, and direct comparisons can also be made be-
tween the three ECM molecules.
Effects of cCAF and its peptides on the production of TN
In adults, TN, specifically TN C, is present almost exclu-
sively in the granulation tissue of healing wounds [12,24].
In addition to providing a matrix for rapid migration of
cells during wound repair, TN supports differentiation of
fibroblasts into myofibroblasts [25], which then produce
more TN than do normal fibroblasts [15,18]. Because
cCAF stimulates fibroblasts to differentiate into myofi-
broblasts, we tested the possibility that this chemokine
also affects TN production. Immunolabeling of cells treat-
ed daily for four days with 750 ng/ml of the chemokine
showed that cCAF stimulates the cells to produce more TNPage 2 of 15
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Effect of cCAF on TN levels in culture.(A-D) Embryonic connective tissue fibroblasts immunolabeled for TN. (A) In
untreated cultures, some fibroblasts show a small amount of staining for this protein, which is characteristic of CEFs in culture.
(B&C) Cultures treated for 3 days with cCAF (B) or with the N-terminal peptide (C) show that more fibroblasts stain for TN
and that the staining is more intense than for untreated cells. (D) Treatment of cells with the C-peptide has a smaller effect on
the number of cells staining for TN. (E) Immunoblot analysis for TN to quantify the results observed in (A-D). All lanes con-
tained equal amounts of total protein, as measured by the DC protein assay (BioRad). Cells treated with cCAF or the N-pep-
tide for 3 days show higher levels of TN than untreated or C-peptide treated cells. (F) Northern blot analysis of TN mRNA.
Fibroblasts were treated with cCAF or its terminal peptides, total RNA extracted using TRIzol reagent and RT-PCR was per-
formed as described in Materials and Methods. Amplification of TN mRNA reveals a substantial increase inTN mRNA with
cCAF and N-peptide treatments whereas the C-peptide stimulated a small increase. To quantify the amount of RNA present,
an internal control against 18S rRNA was used.Page 3 of 15
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determined, using dose-dependent studies, that this con-
centration is optimal for functions of this chemokine on
these embryonic fibroblasts and in processes of granula-
tion tissue formation [3,4]). Although chemokine con-
centrations of 10-2-10 ng/ml can chemoattract and
activate leukocytes, chemokines acting on other cell types
such as endothelial cells, smooth muscle cells and fibrob-
lasts require concentrations in the range of 102ng/ml and
higher [4,26–28]. This is within physiological range; for
example wound fluid from burn patients contain MGSA
(a chemokine that is highly homologous to cCAF) con-
centrations of 102–103ng/ml [29]. Because both the N-
terminal and C-terminal peptides of cCAF have been
shown to be functional in culture and in vivo (1–4, 30), we
also tested these two peptides (Fig. 1). The N-terminal
15aa peptide produced an effect at least as strong as the
whole molecule (Fig. 1C) whereas the effects of the C-ter-
minal peptide (28aa) was closer to those of the control
(Fig. 1D). Western blot analysis of extracts from treated fi-
broblasts confirmed that cCAF increases production of TN
in culture, that this effect also can be accomplished effec-
tively by the N-peptide, but that the C-peptide produced
an elevated, but substantially smaller, response than ei-
ther the N-peptide or the whole cCAF molecule (Fig. 1E).
To determine whether cCAF stimulates TN expression we
examined the levels of mRNA for this ECM molecule. RT-
PCR analysis showed significant increased levels of mRNA
for TN after treatment with either cCAF or its N-peptide
(Fig. 1F) but the increase stimulated by the C-terminus is
much smaller correlating with the small increase in pro-
tein levels.
To determine whether this effect is also observed in vivo,
excision wounds were made on the underside of wings of
2 week-old chicks. To avoid variations in genetic back-
ground, for each bird one wing was treated with vehicle
and the other with cCAF, and treatments were applied eve-
ry other day for 5 days. In normal wound healing, TN ap-
peared at days 2–3 and disappeared during remodeling
which begins around day 10 after wounding. Therefore,
tissues were collected at days 3 and 7 after wounding and
analyzed for TN by immunostaining and western blot
analysis (Fig. 2A & 2B). Immunoblot analysis of protein
extracted from control wounds confirmed that TN deposi-
tion begun by 3 days and that it increased dramatically by
7 days (Fig. 2C, Control). In contrast, by 3 days, cCAF-
treated wounds already contained as much TN as the con-
trol at 7 days and that by 7 days, the TN is dramatically re-
duced by the ongoing processes of repair (Fig 2C, cCAF).
Thus, the addition of the chemokine to wounds shifts the
peak of TN in the wound tissues to earlier stages of wound
healing than in control wounds.
Figure 2
Levels of TN in the granulation tissue of excision
wounds. Paraffin-embedded sections of excision wounds
treated every other day with vehicle or 1 µg cCAF were
immunostained with an antibody against TN. At 3 days after
wounding, control wounds (A) show almost no labeling for
TN whereas those treated with cCAF already show substan-
tial labeling for TN (B). (C) Immunoblot analysis of proteins
extracted from treated and control tissues reveals that treat-
ment with cCAF results in greatly increased levels of TN
within 3 days after wounding, but that by seven days, the
amount of TN in the treated wounds had decreased whereas
untreated wounds showed levels similar to those of cCAF
treated at 3 days. All lanes contain equal amounts of total
protein, as measured by the DC protein assay (BioRad).Page 4 of 15
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Effect of cCAF on FN levels in culture. Embryonic connective tissue fibroblasts immunolabeled for FN. (A) Untreated 3
day-old cultures show FN fibers over the cells. (B) Cultures treated with cCAF for 3 days show more fibers, and the staining
is more intense than those in the controls. (C,D) Cells treated with the same amounts of N-peptide or C-peptide have levels
of FN similar to control. (E) Immunoblot analysis of cells treated with cCAF show higher levels of FN than untreated or pep-
tide-treated cells. All lanes contain equal amounts of total protein, as measured by the DC protein assay (BioRad). (F) North-
ern blot analysis for FN shows no difference in mRNA levels between control and cells treated with cCAF for times up to 48
hours.Page 5 of 15
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Cellular FN is abundantly present in granulation tissue, is
produced primarily by the wound fibroblasts and myofi-
broblasts. Fibroblast cultures treated as for TN, produced
much more FN, as shown by immunolabeling (Figs. 3A &
3B) and immunoblot analysis (Fig. 3E). Unlike TN, this
effect can only be accomplished by the whole cCAF mole-
cule; immunolabeling and immunoblot analysis of cells
treated with the N-peptide (Fig. 3C & 3E) or C-peptide
(Fig. 3D & 3E) revealed similar FN levels to control. Un-
like TN, cCAF did not affect FN mRNA levels (Fig. 3F). In
vivo, immunostaining for FN, 3 days after making exci-
sion wounds, showed that levels of this protein are high
in the healing tissues and that treatment with cCAF in-
creased FN accumulation in the granulation tissue (Fig.
4A & 4B). Immunoblot analysis for FN extracted from ex-
cision wounds showed that by 3 days after injury the
cCAF-treated wounds contained more FN than the control
wounds but that the levels by 7 days are similar to those
of the control (Fig. 4C).
Taken together the results in culture and in vivo suggest
that the chemokine does not stimulate FN gene expres-
sion but rather may directly or indirectly affect stability of
this protein. Therefore, we tested the possibility that cCAF
treatment leads to stability of the protein by stimulating
decrease in matrix degrading enzymes. In chickens, plas-
min generated from plasminogen by plasminogen activa-
tor (PA) degrades much of the FN. To investigate whether
activity of PA might be decreased with cCAF treatment
leading to accumulation of FN, we examined the levels of
PA activity. Our results showed that there is no detectable
PA activity in untreated or treated fibroblasts whereas the
activity is high in RSV-transformed CEFs (tCEFs; Fig. 5A)
which are known to produce high levels of PA [31]. Be-
cause PA does not appear to be activated by cCAF, we test-
ed the possibility that the stability of FN is due to a
decrease in MMP production/activation. In humans,
MMP-3, MMP-7 and MMP-10 (stromelysins) are the most
active proteases for FN, but these molecules have not been
isolated in chickens. However, we can test for general ac-
tivity of these MMPs in the chicken system by zymography
using casein as substrate (Fig. 5B). Whereas the positive
control (trypsin) was able to digest the substrate at specific
sites in the gel, the supernatants of our treated fibroblasts
did not. This suggests that the stromelysins are not active
in this system or that our test is not sensitive enough. To
further investigate whether MMPs are involved in the
cCAF induced high levels of FN will require evaluation of
matrix-degrading enzymes specific for chickens and is an
ongoing project in our laboratory as we obtain/develop
probes for theses MMPs. However, another possible
mechanism for the cCAF-induced FN accumulation could
be linked to an increase in TN. TN-C knockout mice show
decreased accumulation of FN in wounded tissue and this
decrease has been hypothesized to be due to disrupted in-
corporation of FN into the matrix in the absence of TN-C
[32,33]. To determine whether cCAF-induced TN produc-
tion is involved in the increase in FN observed after cCAF
treatment, we used antisense phosphothioated oligonu-
cleotides to inhibit TN production. Sense oligonucle-
otides did not have an effect on cCAF-induced TN or FN
production. However, the antisense oligonucleotides
were able to significantly decrease the production of both
TN and FN (Fig. 5C).
Effects of cCAF and its peptides on the production of Colls 
I and III
To determine whether cCAF stimulates fibroblasts to pro-
duce increased levels of Colls I and III, we treated cultures
as for TN. Immunoblot analysis for Coll I showed that
cCAF, but not the N- or C-peptides, caused a small in-
crease in Coll I protein levels (Fig. 6A). Probing the same
blots for Coll III revealed no cCAF-induced difference in
the level of production of this protein (Fig. 6B). In vivo,
Coll I was also slightly increased by treatment with the
chemokine at 3 days after wounding but did not increase
to higher levels than the control at 7 days, whereas the
same blots probed for Coll III showed similar levels in
treated and control at both 3 and 7 days (Figure 6C).
The effect on Coll I could be due to remodeling of this
protein by proteases induced by the chemokine. There-
fore, we tested whether cCAF affects the production or ac-
tivity of the gelatinases MMP-2 or MMP-9, or the
collagenase MMP-1, all of which digest collagens I and III.
Using zymography, we found that treatment with cCAF or
the peptides does not alter the levels of proMMP-2 and
there was no detectable levels of proMMP-9 (Fig. 7A).
However, immunoblot analysis using a polyclonal anti-
body to human MMP-1 (this reagent is not available for
the chicken homologue of this matrix metalloproteinase)
showed that cCAF treatment caused a decrease in the
amount of the collagenase MMP-1 detected, but neither
TIMP-1 nor TIMP-2 (two natural inhibitors of these
MMPs) levels were changed, as evaluated by immunoblot
analysis with a monoclonal antibody to the correspond-
ing human proteins (Fig. 7B).
Effects of cCAF on migration of fibroblasts
During healing, fibroblasts migrate into and within the
wounded tissue and lay down the extracellular matrix that
forms the granulation tissue. These ECM molecules, espe-
cially TN and FN together, stimulate cell migration, there-
by facilitating the entrance and movement of additional
fibroblasts and of endothelial cells into the wound tissue.
Because tissues treated with cCAF have more FN and TN at
the time that these cells are entering the wound and chem-
okines are well known for their chemoattractant proper-
ties [34,35], we tested whether cCAF stimulatesPage 6 of 15
(page number not for citation purposes)
BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/13chemotaxis of fibroblasts using transwell assays. To avoid
effects of gravity on cell migration, the top chamber was
inverted, the cells were plated on the underside of the
membrane, allowed to adhere to it and then the chamber
was turned right side up. The cells were incubated over-
night in standard medium to allow expression of the cCAF
receptor(s) and the following day cCAF was applied at in-
creasing doses (100–1000 ng/ml) to the top chamber on-
ly. The migration assays were carried out for 24 hrs. We
found that cCAF stimulated migration of the fibroblasts
up the concentration gradient in a dose-dependent man-
ner (Fig. 8A). To test whether the cCAF-induced effect is
due to chemotaxis, we repeated the transwell assay and
compared cell migration when cCAF is added to both
wells. Placing cCAF in both wells abrogated cell migra-
tion, strongly suggesting that this protein chemoattracts fi-
broblasts (Fig 8B). We also tested the effects of the
chemokine on migration by using the cloning ring assay.
In a specified length of time, cells treated with cCAF
moved a longer distance than did control cells, corrobo-
rating the previous results that the chemokine stimulates
cell motility (Fig. 8C). In situ hybridization for cCAF
showed that the migrating fibroblasts also express higher
levels of cCAF (Fig. 8D & 8E; see also ref. [36]).
Discussion
The work presented here shows that cCAF, the IL-8 of
chickens, stimulates expression of several ECM molecules
important in development of the granulation tissue. We
show that: (i) cCAF stimulates TN expression and that a
15 aa peptide containing the N-terminal sequence causes
the same effects as the whole molecule; (ii) in contrast to
its effects on TN production, cCAF-induced increase in FN
and Coll I accumulation requires the whole molecule;
(iii) the increase in FN protein is not a result of a corre-
sponding increase in mRNA, or increase in MMP produc-
tion or PA activity but appears to be linked TN
production; (iv) increase in Coll I correlates with de-
creased levels of MMP-1; (v) cCAF chemoattracts fibrob-
lasts and accelerates their migration; (vi) treatment of
excision wounds with cCAF increased the levels of all
three ECM molecules in the granulation tissue of wounds
albeit with different dynamics. This is the first demonstra-
tion that treatment of wounds with a pro-inflammatory
and angiogenic chemokine accelerates development of
the granulation tissue during healing by stimulating the
precocious deposition of ECM molecules that are critical
for proper healing.
We showed previously that cCAF is highly expressed in the
granulation tissue of wounds [6,36], that this chemokine
and several of its human homologues stimulate differen-
tiation of fibroblasts into myofibroblasts both in culture
and in vivo, and that the latter effect can be achieved very
effectively by the N-terminal 15aas of the protein [4,37].
Figure 4
Levels of FN in the granulation tissue of excision
wounds. Paraffin-embedded sections of excision wounds
treated every other day with vehicle or 1 µg cCAF were
immunostained with an antibody to FN. Three days after
wounding, control wounds (A) show less labeling for FN
than those treated with cCAF (B). (C) Immunoblot analysis
of protein extracted from treated and control wounds
reveals that treatment with cCAF causes increased FN levels
at 3 days but at 7 days the FN protein levels to approxi-
mately the levels of the control.Page 7 of 15
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sociated with wound healing events. In the granulation
tissue of burn wounds, expression of groα /MGSA and
CXCR2 (the receptor for MGSA) was associated with fi-
broblasts, smooth muscle cells/myofibroblasts and a sub-
population of macrophages [7]. Groα/MGSA and IL-8
have also been shown to enhance re-epithelialization of
human skin grafts in chimeric mice [29,38]. It has also
been found that several CXC chemokines can modulate
angiogenesis [39], a process that is critical for proper heal-
ing. Some CXC chemokines, such as IL-8 and cCAF, are
angiogenic in vivo[3,39–41]. Others, such as IP-10 (inter-
feron-γ10) and PF-4 (platelet factor-4), are anti-angiogen-
ic. In the case of IP-10, it has been shown that in
transgenic mice treated with this chemokine, wounds heal
poorly and exhibit defects in angiogenesis and develop-
ment of the granulation tissue [8].
Work of others has shown that TN is expressed in associa-
tion with differentiation of myofibroblasts and is impor-
tant in cell migration during healing [25,42–44]. Here we
show that cCAF and the N-peptide stimulate fibroblasts in
culture to express TN and that this increase in TN is due to
an increase in mRNA levels. The increase is lower for C-
peptide treated cells; after 3 days in an environment mim-
icking the wound, these cells had lesser but significant te-
nascin protein levels, most likely due to the small increase
seen in mRNA. In addition, in wounds treated with the
chemokine, TN levels are much higher at early times after
wounding but drop by 7 days after wounding. At this
stage, the wounds are closed and are beginning to remod-
el in the cCAF-treated wounds while the granulation tis-
sue in the control wings is still maturing. These data taken
together strongly suggest that as chemokines induce the
differentiation of fibroblasts into myofibroblasts they
contribute to the production of TN in the granulation tis-
sue. Our finding that the N-terminal peptide is able to
stimulate expression of TN much like the whole protein is
potentially important because this small peptide may be
useful to develop therapeutic agonists or antagonists for
wound healing.
The effect of cCAF treatment on Coll I accumulation in
culture and in wounded tissues is small but reproducible.
Because MMP-1 levels were also decreased by cCAF treat-
ment, it is possible that the small rise in Coll I levels is due
to decreased degradation of this ECM molecule by the col-
lagenase. Another chemokine that has been associated
with Coll I production is monocyte chemotactic protein 1
(MCP-1). This chemokine belongs to the CC chemokine
family and stimulates Coll I production both by lung fi-
broblasts taken from areas of inflammation [26] and in
kidneys that suffer from crescentic nephritis [45]. The
former investigators reported that MCP-1 increases colla-
gen accumulation not by decreasing the levels of the col-
Figure 5
Potential mecahnisms for cCAF-induced FN accumu-
lation.(A) Analysis of plasminogen activator (PA) activity.
Using a synthetic chromogenic substrate (Boc-Val-Gly-Arg-β
NA.AcOH) there was an increase in fluorescence detected in
supernatant from Rous sarcoma virus transformed fibrob-
lasts which secrete large amounts of PA but not with the
control or cCAF-treated supernatants. (B) Casein zymogra-
phy to detect MMP-3, MMP-7, and MMP-10. No detectable
caseinolytic activity in the supernatant of control or cCAF-
treated fibroblast was found. The general protease trypsin
was used as a positive control. Because this enzyme is not
pure, multiple sites of protein digestion were seen. (C)
Blocking TN expression using antisense oligonucleotides.
Immunoblot analysis of TN and of FN; equal amounts of pro-
tein, as determined by using the DC protein assay kit (Bio-
Rad),were loaded in each lane. Use of antisense TN oligos
blocked the cCAF-induced expression of both FN and TN,
whereas the use of sense oligos had no effect on TN or FN
levels.
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BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/13lagenase MMP-1, but by stimulating the production of
TGFβ1, a well-known stimulator of collagen expression
and expression of TIMPs, the natural inhibitors of MMPs.
In addition to MCP-1, IL-8 and MGSA have also been
evaluated for production of collagen [46]. These investiga-
tors reported that treatment of normal fibroblasts with
these chemokines did not affect collagen levels. It is not
clear from their results whether the elevation in collagen
production in normal fibroblasts may have been small,
like that observed with cCAF, and therefore gone unno-
ticed.
FN accumulation due to cCAF treatment also differs from
that of TN. The FN mRNA levels are not affected by cCAF
treatment but the protein accumulates in culture and in
the granulation tissue of wounds upon exposure to the
chemokine. By analogy with the increase in Coll I, we hy-
pothesized that decrease in protease levels/activity is in-
volved in the accumulation of FN. Plasmin resulting from
cleavage of plasminogen by plasminogen activator (PA) is
the major enzyme affecting FN degradation in chickens.
However, testing for decrease in PA activity showed that
this enzyme is not activated even in the controls, there-
fore, it is unlikely that this would be a major mechanism
involved in degrading FN. In humans, there are several
MMPs that are known to degrade FN. We found that
MMP-2 levels are unaffected by cCAF treatment and that
there is no detectable MMP-3, -7 and -10 activity as evalu-
ated by casein zymography using tCEFs as control for pro-
duction of these stromelysins. Another FN-degrading
metalloproteinase, MT-MMP1, is unlikely to be involved
because it also activates MMP-2 and this enzyme is not ac-
tivated by cCAF treatment.
Another possible mechanism that may explain FN accu-
mulation could be an increase in TN. TN-C knockout mice
show decreased accumulation of FN in wounded tissue
and this decrease has been hypothesized to be due to dis-
rupted incorporation on FN into the matrix in the absence
of TN-C [32,33]. Therefore, our observation that inhibi-
tion of cCAF-induced TN production decreases the accu-
mulation of FN supports the findings in the knockout
mice. However, this does not explain the unchanged FN
levels with the N-peptide treatment. One possible expla-
nation for these findings could relate to the fact that FN
does not self-assemble. Therefore, it is possible that alter-
ations in the activities of integrins or adhesive sites on
other ECM molecules induced by the whole cCAF mole-
cule, and not by the N-peptide, could affect FN accumula-
tion [47]. We are currently pursuing studies to determine
whether adhesion molecules or other ECM molecules
play a role in FN accumulation due to cCAF-induced TN
production.
Figure 6
Effect of cCAF on collagen levels.(A&B) Immunoblot
analysis for Colls I and III, respectively. All lanes contain equal
amounts of total protein, as measured by the DC protein
assay (BioRad). Treatment of fibroblasts with cCAF, but not
the C- or N-peptides, stimulates a small but reproducible
increase in protein levels of Coll I when compared with
untreated cells (A). Neither cCAF nor peptide treatments
changed Coll III levels (B).(C) Levels of Colls I and III in
wounds treated with cCAF. Immunoblot analysis of protein
extracts from wounded wings treated with 1 µg of cCAF
were performed as described in Materials and Methods sec-
tion. Coll I levels are slightly higher than those of the control
after 3 days of treatment with cCAF. However, they are sim-
ilar to those of the control at 7 days. Coll III levels do not dif-
fer between control and cCAF-treated wings.
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wound into the wound site is critical in order for remode-
ling of the extracellular matrix and for wound contraction
to occur. TN and FN, especially in combination, promote
migration, therefore cCAF may facilitate fibroblast migra-
tion by increasing TN and FN levels. However, this chem-
okine is also able to chemoattract fibroblasts and
accelerate their migration in the absence of these mole-
cules, strongly suggesting that it contributes to fibroblast
movement independently of the deposition of these ECM
molecule. These findings suggest that during wound heal-
ing, cCAF produced by the resident fibroblasts chemoat-
tracts additional fibroblasts that contribute to the
production of these ECM molecules, which then support
migration of both fibroblasts and other cells in the wound
tissue.
TGFβ1 is another factor known to stimulate myofibrob-
last differentiation, ECM production and accelerate
wound closure and healing. However, this growth factor
has a strong inflammatory effect that leads to excess fibro-
sis and scarring. In addition to greatly increasing accumu-
lation of Colls I and III, TGFβ1 has been shown to also
increase FN and TN production. cCAF (and maybe other
chemokines), on the other hand, may have a subtler,
more controlled effect, promoting the earlier appearance
of a normal granulation tissue without leading to excess
matrix accumulation and scarring.
Conclusions
Our results strongly suggest that cCAF plays an important
role in wound repair by activating fibroblasts to form ear-
ly granulation tissue, through cell migration, myofibrob-
last differentiation and production/accumulation of ECM
molecules that are critical for proper development of the
healing tissue of wounds. This is a previously unknown
role for chemokines and, unlike other inflammatory fac-
tors that promote granulation tissue formation, cCAF
does not appear to stimulate increased fibrosis. If similar
behavior is seen in human chemokines, it could be a
promising target in designing drugs that promote forma-
tion of granulation tissue in poorly healing wounds with-
out causing excess scarring.
Materials and methods
Reagents
All tissue culture supplies and the TRIzol reagent were
purchased from Gibco-BRL. cCAF and the N-terminal
peptide (15a.a.) were synthesized by Gryphon Sciences
(San Francisco, CA) and C-terminus peptide (28a.a) was
made by Milligen Biosearch (San Rafael, CA). Secondary
antibodies used: anti-mouse and anti-rabbit horseradish
peroxidase, anti-mouse Texas Red (Amersham: Piscata-
way, NJ) and anti-mouse FITC (DAKO: Carpinteria, CA).
Primary antibodies used: mouse anti-chicken Coll I, Coll
III, FN, and TN (Hybridoma Bank, Iowa), rabbit anti-
chicken TN (Chemicon, Temecula CA). Rabbit anti-hu-
man MMP-1 and TIMP-2 and mouse anti-human TIMP-1
were the kind gift of Dr. Tai-Lan Tuan. The ECL reagents
were purchased from Amersham; Vectashield mounting
medium from Vector Laboratories (Burlingame, CA); DC
protein assay kit from Bio-Rad (Hercules, CA); Biocoat
and Transwells from Fisher and Biocclusive bandage from
Johnson&Johnson Medical (Arlington, TX).
Cell culture
Primary chicken embryonic fibroblasts were cultured as
previously described [3,4]. Briefly, primary fibroblasts
Figure 7
Effect of cCAF on the gelatinases, MMP-2 and -9.(A)
Gelatin zymography of supernatants from cCAF-treated
fibroblasts. The cells produce only detectable levels of pro-
MMP-2 and neither cCAF nor its terminal peptides affects
MMP activity levels. No proMMP-9 or activated form, were
detected. Human aortic endothelial cells (hAEC) which pro-
duce and activate MMP-2 and produce pro-MMP-9 were
used as positive control. (B) Immunoblots of the fibroblast
supernatants. The levels of the MMP-1 protein are slightly
but reproducibly decreased by treatment with the whole
cCAF molecule but not by either of its terminal peptides.
The levels of TIMP-1 and TIMP-2, the natural inhibitors for
some MMPs, are not affected by treatment with cCAF or its
peptides.
B
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Effect of cCAF on fibroblast migration(A) Using Transwell membrane assays we determined that treatment of fibroblasts
with cCAF for 24 hours resulted in increased migration toward the chemokine. This effect is dose-dependent with an increase
detected at doses of 100 ng/ml and strongest at a dose of 1000 ng/ml. Serum-containing medium was used as positive control.
(B) When fibroblasts were treated with 1000 ng/ml cCAF in both wells migration to the upper side of the membrane was
abrogated. (C) Fibroblasts plated inside a cloning ring. Cells were allowed to migrate away from the edges of the ring for 2
days while treated with 100–1000 ng/ml cCAF. Treatment with cCAF resulted in a significant increase in the distance migrated
by the fibroblasts (* = p < 0.05; n = 4). (D&E)In situ hybridization shows that the fibroblasts migrating away form the edge
express cCAF. Dash-dot lines show the edge of the culture after scraping. In (D) arrowheads point to cells labeling with the
antisense probe for cCAF whereas in (E) they point to scattered labeling over the cells incubated with the sense probe.Page 11 of 15
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tured for 4 days. These cultures were passaged once and
used as secondary cultures at a density of 0.3 × 106 cells/
35 mm plate. Due to the use of primary cells rather than
cell lines, there are variations in cellular responses be-
tween sets of cells. Therefore, internal controls were al-
ways included and results from different batches of cells
were not averaged. Secondary cultures were treated with
750 ng/ml cCAF [68 nM] or its terminal peptides in 199/
tryptose phosphate broth and 2% donor calf serum. This
dose of cCAF was chosen because it was the optimal dose
for inducing differentiation of myofibroblasts, cells
known to produce large amounts of ECM [4]. Media was
changed and new cCAF or peptides added every day for 4
days.
Immunoblotting
Proteins were extracted from the cells after 4 days of treat-
ment, using 150 mM RIPA buffer containing protease in-
hibitors. Protein concentrations were determined using
the DC protein assay kit (Bio-Rad) and samples were ad-
justed to contain equal amounts of protein. Proteins were
separated on 7.5% Doucet gels [48] and transferred to ni-
trocellulose was performed using a wet-transfer apparatus
(Bio-Rad) at 100 V for 45 min. The membranes were
blocked for 1 h in 5% milk in TTBS and then incubated
overnight at 4°C in primary antibody (1:50 anti-Coll I,
anti-Coll III and anti-FN, 1:100 TIMP-1, 1:500 anti-MMP-
1 and anti-TIMP-2, 1:1000 anti-TN), in 1% milk in TTBS.
The membranes were washed 3 times for 10 min each
with TTBS, incubated in anti-mouse or anti-rabbit HRP
(1:10,000) in 1% milk for 1 hr and washed as above, the
bands visualized using the ECL (Amersham). Densitome-
try was performed using BandScan software (Glyko).
Immunostaining
At the end of treatment, the cells were rinsed with PBS,
fixed and permeabilized in 4% paraformaldehyde with
0.15% Triton X-100. After fixation, the cells were washed
and then incubated with PBS containing 0.1 M glycine for
10 min. Cells were blocked for 30 min with 10% goat se-
rum in PBS, incubated with primary antibody (1:100) in
1%BSA/PBS for 1 hr at room temperature (RT), and
washed three times with 0.1% BSA/PBS for 10 min each.
The cells were then incubated in secondary antibody in
1% BSA/PBS for 1 hr at RT, washed three times for 10 min
with 0.1% BSA in PBS and mounted with Vectashield.
Zymography
Zymography was performed using denaturing polyacryla-
mide gels according to the protocol of ref. [49]. Gels to test
for gelatinolytic activity contained 1% gelatin (Sigma)
and those that tested for caseinolytic activity had 1% ca-
sein (Sigma). 5 µl of 0.25% trypsin-EDTA (Gibco-BRL)
was used as a positive control for the casein zymogram.
Plasminogen activity assay
A chromogenic plasminogen activator substrate (Boc-Val-
Gly-Arg-βNA.AcOH) was purchased from Calbiochem. 50
µl of a 10 mM stock solution of substrate in water was
added to 200 µl 0.1 mM HEPES buffer pH 8.0 and heated
to 25°C. 25 µl fibroblast substrate was added to the sub-
strate and incubated for 30 min. Absorbance was then
read at 405 nm. Positive control: Supernatant from Rous
sarcoma virus-transformed CEFs (tCEFs), which are
known to produce high levels of PA.
Inhibition of TN expression
For these experiments we used phosphothioated antisense
oligodeoxynucleotide (ODN), synthesized and HPLC pu-
rified by Sigma Genosys, to block the TN production. The
sequences for the oligonucleotides were the same as pre-
viously described [50] except that we used phosphothio-
ated oligos rather than morpholino oligos. The antisense
sequence of the ODN was 5'-GGAGTCCCATTGTAGT-
GCTCAGTTC-3'. The sense strand of this ODN was used
as control (5'-GAACTGAGCACTACAATGGGACTCC-3').
When preparing the cell cultures, 1 µM and 2 µM of anti-
sense or sense ODN were added to the cells at plating. The
cells where treated with antisense or sense ODN and cCAF
every 24 hrs for 3 days to allow accumulation of the ECM
molecules.
Northerns
Total RNA was extracted using TRIzol reagent from un-
treated fibroblasts and fibroblasts treated with 750 ng/ml
cCAF for 4–48 hrs. Transfer of RNA to membrane was per-
formed as previously described [51]. RNA probes were
made using the Strip-EZ kit from Ambion (Arlington, TX).
Membranes were prehybridized for 2 hrs in Ambion Hy-
bridization buffer at 62°C, and hybridized O/N at 62°C.
Membranes were washed with 2 × SSC/0.1% SDS at 62°C
and exposed to film for 6–48 hrs.
RT-PCR
Total RNA was extracted as above. RT-PCR was performed
using the Promega Access RT-PCR System, following
Promega's instructions. The first strand was synthesized at
48°C and DNA was amplified at 95°C 45 sec, 55°C 1 min,
68°C 1.5 min for 40 cycles. 3 µl Quantum mRNA classic
18S primers from Ambion were used to quantify total
RNA levels. Primers used for TN amplification: sense
5'AAATGCATCTGCGAGGGC, antisense 5"GGAAGCTT-
GTTATTGCAGTCCTTCGG [41].
Wounding experiment
Full-thickness excision wounds (approximately 0.5 × 0.5
cm) were made on the underside of the wings of 2 week-
old chicks, using a scalpel blade. The left wing was treated
with vehicle alone, and the right wing with 1 µg cCAF. The
wounds were photographed immediately after woundingPage 12 of 15
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or cCAF were deposited through the bandage onto the
wound using a 30-gauge needle. This procedure was re-
peated the next day and every other day thereafter on days
3, 5 and 7. Samples were collected at days 3 and 7 post-
wounding for ECM analysis. All experimental work with
animals reported here was done under full compliance
with our animal protocol approved by appropriate cam-
pus authorities.
Preparation and staining of wing sections
At the specified time points, chickens were euthanized
with sodium pentobarbitol. The wounded wings were col-
lected and fixed for 18 hrs in 4% paraformaldehyde and
decalcified for 3 days in 5% formic acid, 2.5% formalde-
hyde at 4°C. The tissue was embedded in paraffin and sec-
tioned. Sections were stained with Masson Trichrome to
visualize interstitial collagen. Other sections were immu-
nolabeled for FN or TN. Sections were deparaffinized in 3
changes of Hemo-De for 15 min each and rehydrated in a
descending ethanol series (5 min each: 100%, 95%, 70%,
50%, 30% ethanol). After rinsing with PBS, sections were
fixed in 2% paraformaldehyde for 1 hr. Autofluorescence
and non-specific staining were blocked for 30 min in 0.1
M glycine in PBS, followed by 30 min in 1% Evans Blue in
PBS to quench red blood cell autofluorescence. Sections
were incubated with anti-FN or anti-TN antibodies (1:50)
in 1% BSA in PBS for 2 hr at room temperature. After 3 ×
10 min washes in 0.1% BSA in PBS, the sections were in-
cubated for 40 min with anti-mouse Alexa antibody
(1:200) in 1% BSA in PBS. They were then washed and
mounted with Vectashield.
Protein extracts of wounds
Wound tissues were immediately frozen on dry ice and
stored at -70°C. To extract protein, the tissue was ground
with glass beads in a mortar and pestle on dry ice. The
powdered tissue was dissolved in RIPA containing 300
mM salt and a cocktail of protease inhibitors, and vor-
texed vigorously. After centrifugation, the supernatant was
used in immunoblots.
Transwell assay for migration
1 × 106 cells in 100 µl 199 medium containing 2% serum
were plated on the underside of transwell membranes by
inverting the insert. They were allowed to adhere for 30
minutes, then the well was turned right side up and both
sides of the well were filled with serum-containing medi-
um. The cells were allowed to recover for 24 hrs, and ex-
press the cCAF receptors. Then the medium in the top well
was changed to serum-free medium containing 50–1000
ng/ml cCAF or 2 % serum (positive control); serum free
medium alone was placed in the bottom well. The cells
were allowed to migrate towards the chemoattractant for
24 hrs. The cells on the underside of the membrane were
removed with a cotton swab. The membranes were then
fixed and stained with 2% toludine blue in formaldehyde.
To determine the number of migrated cells, all cells on the
upper side of the membrane were counted. Control for
chemotaxis was performed by adding 1000 ng/ml cCAF to
both wells of the Transwell unit.
Cloning ring assay for migration
1 × 106 cells in 100 µl 199 medium containing 2% serum
were plated in a cloning ring in a 35 mm plate. They were
allowed to adhere for 1 hour, then the ring was removed,
the culture medium added to the plate and the cells pho-
tographed on a phase-contrast microscope to record the
area of the cells and the edge of the ring. cCAF was then
added at various doses (0–1000 ng/ml). The following
day the medium was changed and the cells were treated
again. On the third day after plating, the cells were photo-
graphed once more before the experiment was terminat-
ed. To determine the extent of cell migration, we
measured the distance between the edge where the clon-
ing ring was at day zero and the edge of the culture delin-
eated by the migrating front of the cells on the 3rd day.
In situ hybridization
Fibroblast cultures and probes were prepared as described
previously (Martins-Green and Bissell, 1990). Briefly,
probes were prepared as follows: 1 µg of pGEM1/cCAF
cDNA was transcribed for 1 1/2 h at 37°C in a cocktail
containing 100 µM each of 3H-ATP and 3H-UTP (Amer-
sham Corp.), 1 mM each GTP and CTP, 120 mM dithio-
threitol, and 100 U of T7 polymerase (Amersham
Corop.). The probe was separated from the free nucle-
otides in a Sephadex G-50 column equilibrated with 50
mM tris(hydroxymethyl) aminomethane pH 8.0, 15 mM
NaCl, and 1 mM EDTA. For in situ hybridization, cells
were fixed in 4% paraformaldehyde containing 5 mM
MgCl2, incubated in 0.1 M glycine for 10 min, dehydrated
3 min each in 30, 70, and 100% ethanol, and allowed to
dry. Prehybridization was performed in a solution con-
taining 60% formamide, 0.1 M piperazine-N,N'-bis(2-
ethanesulfonic acid) pH 6.4, 0.4 M NaCl, and 0.2 mg/ml
of E. coli tRNA (Sigma, St. Louis, MO) for 2 h at 55°C with
gentle shaking. The hybridization solution was the same
as the prehybridization solution but contained 106 cpm/
ml of the cCAF probe or with the same number of counts
of the vector probe and incubated at 55°C for 48 h with
gentle shaking. At the end of this period, the cultures were
washed twice with 2× SSC + 0.1% Triton-X 100 for 1 h fol-
lowed by two more washes with 0.1× SSC + 0.1% Triton-
X 100, all at 55°C in the shaker. The cultures were allowed
to dry, then covered with emulsion and processed as de-
scribed previously [6].Page 13 of 15
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List of abbreviations used
cCAF chicken Chemotactic and Angiogenic Factor
CEFs chicken embryo fibroblasts
Coll collagen
ECM extracellular matrix
FN fibronectin
IL-8 interleukin-8
MCP-1 monocyte chemotactic protein-1
MGSA melanoma growth stimulatory activity
MMP matrix metalloprotease
PA plasminogen activator
TGFβ1 transforming growth factor β1
TIMP tissue inhibitor of metalloprotease
TN tenascin
Acknowledgements
We thank Ibsen Chen for assistance with the preparation and sectioning of 
the wing tissues. Dr. Tai-Lan Tuan kindly provided us with the MMP and 
TIMP antibodies. This work was supported in part by a Dissertation Re-
search Grant from the University of California, Riverside and a GAANN 
fellowship (U.S. Department of Education) to JEF and by NIH grant 
GM48436 to MM-G.
References
1. Clark-Lewis I, Kim K, Rajarathnam K, Gong J, Dewald B, Moser B, et
al: Structure-activity relationships of chemokines. J Leukoc Biol
1995, 57:703-711
2. Weber M, Uguccioni M, Baggiolini M, Clark-Lewis I, Dahinden C: De-
letion of the NH2-terminal residue converts monocyte
chemotactic protein 1 from an activator of basophil release
to an eosinophil chemoattractant. J Exp Med 1996, 183:681-685
3. Martins-Green M, Feugate J: The 9E3/CEF4 gene product is a
chemotactic and angiogenic factor that can initiate the
wound healing cascade in vivo. Cytokine 1998, 10:522-535
4. Feugate J, Li QJ, Wong L, Martins-Green M: The CXC chemokine
cCAF stimulates differentiation of fibroblasts into myofi-
broblasts and accelerates wound closure. J Cell Biol 2002,
156:161-72
5. Furie M, Randolph G: Chemokines and tissue injury. Am J Pathol
1995, 146:1287-301
6. Martins-Green M, Bissell M: Localization of 9E3/CEF-4 in avian
tissues: expression is absent in Rous sarcoma virus-induced
tumors but is stimulated by injury. J Cell. Biol 1990, 110:581-595
7. Nanney L, Muellaer S, Bueno R, Pieper S, Richmond A: Distribution
of melanoma growth stimulatory activity or growth-regulat-
ed gene and the interleukin-8 receptor in human wound re-
pair. Am J Pathol 1995, 147:1248-1260
8. Luster A, Cardiff R, MacLean J, Crowe K, Granstein R: Delayed
wound healing and disorganized neovascularization in trans-
genic mice expressing the IP-10 chemokine. Proceedings of the
Association of American Physicians 1998, 110:183-196
9. Kaiser P, Hughes S, Bumstead N: The chicken 9E3/CEF4 CXC
chemokine is the avian orthologue of IL-8 and maps to chick-
en Chromosome 4 syntenic with genes flanking the mamma-
lian chemokine cluster. Immunogenetics 1999, 49:673-684
10. Martins-Green M, Hanafusa H: The 9E3/CEF4 gene and its prod-
uct the chicken chemotactic and angiogenic factor (cCAF):
potential roles in wound healing and tumor development. Cy-
tokine Growth Factor Rev 1997, 8:221-232
11. Martins-Green M, Aotaki-Keen A, Hjelmeland L, Bissell M: The 9E3
protein: immuno-localization in vivo and evidence for multi-
ple forms in culture. J Cell Sci 1992, 101:701-707
12. Mackie E, Halfter W, Liverani D: Induction of tenascin in healing
wounds. J Cell Biol 1988, 107:2757-2767
13. Clark R: Basics of cutaneous wound repair. J Dermatol Sur. Oncol
1993, 19:693-706
14. Gabbiani G: The cellular derivation and the life span of the my-
ofibroblast. Pathol Res Pract 1996, 192:708-711
15. Powell D, Mifflin R, Valentich J, Crowe S, Saada J, West A: Myofi-
broblasts. I. Paracrine cells important in health and disease.
Am J Physiol 1999, 277:C1-9
16. Berndt A, Kosmehl H, Katenkamp D, Tauchmann V: Appearance of
the myofibroblastic phenotype in Dupuytren's disease is as-
sociated with a fibronectin, laminin, Coll type IV and TN ex-
tracellular matrix. Pathobiology 1994, 62:55-8
17. Jester J, Barry-Lane P, Cavanagh H, Petroll W: Induction of alpha-
smooth muscle actin expression and myofibroblast transfor-
mation in cultured corneal keratocytes. Cornea 1996, 15:505-
516
18. Serini G, Gabbiani G: Mechanisms of myofibroblast activity and
phenotypic modulation. Exp Cell Res 1999, 250:273-283
19. McCrudden R., Iredale J: Liver fibrosis, the hepatic stellate cell
and tissue inhibitors of metalloproteinases. Histol Histopathol
2000, 15:1159-1168
20. Brown L, Dubin D, Lavigne L, Logan B, Dvorak H, Van de Water L:
Macrophages and fibroblasts express embryonic fibronectins
during cutaneous wound healing. Am J Pathol 1993, 142:793-801
21. Lin R, Adzick NS: The role of the fetal fibroblast and transform-
ing growth factor-beta in a model of human fetal wound re-
pair. Semin Pediatr Surg 1996, 5:165-74
22. Broker B, Chakrabarti R, Blynman T, Roesler J, Wang M, Srivatsan E:
Comparison of growth factor expression in fetal and adult fi-
broblasts: a preliminary report. Arch Otolaryngol Head Neck Surg
1999, 125:676-80
23. Thibeault S, Li W, Gray S, Chen Z: Instability of extracellular ma-
trix gene expression in primary cell culture of fibroblasts
from human vocal lamina propria and tracheal scar. Ann Otol
Rhinol Laryngol 2002, 111:8-14
24. Latijnhouwers M, Bergers M, Van Bergen B, Spruijt K, Andriessen M,
Schalkwijk J: Tenascin expression during wound healing in hu-
man skin. J Pathol 1996, 178:30-35
25. Imanaka-Yoshida K, Yokoyama K, Sakakura T, Yoshida T: Roles of
tenascin-C during myocardial tissue repairing. Mol Biol Cell
2000, 11:48a
26. Gharaee-Kermani M, Denholm E, Phan S: Costimulation of fibrob-
last collagen and transforming growth factor β1 gene expres-
sion by monocyte chemoattractant protein-1 via specific
receptors. J Biol Chem 1996, 271:17779-17784
27. Luo Y, D'Amore P, Dorf M: β-chemokine TCA3 binds to and ac-
tivates rat vascular smooth muscle cells. J Immunol, 1996,
157:2143-8
28. Gupta S, Singh J: Inhibition of endothelial cell proliferation by
platelet factor-4 involves a unique action on S phase progres-
sion. J. Cell Biol 1994, 127:1121-27
29. Rennekampff H, Hansbrough J, Woods V, Dore C, Kiessig V, Schrod-
er J: Role of melanoma growth stimulatory activity (MGSA/Page 14 of 15
(page number not for citation purposes)
BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/13gro) on keratinocyte function in wound healing. Arch Dermatol
Res 1997, 289:204-212
30. Martins-Green M, Kelly T: The Chicken Chemotactic and Ang-
iogenic Factor (cCAF): Its Angiogenic Properties Reside in
the C-Terminus of the Molecule. Cytokine 1998, 10:819-829
31. Alexander D, Aimes R, Quigley J: What structure and function of
avian plasminogen activator and matrix metalloprotease-2
reveals about their counterpart mammalian enzymes, their
regulation and their role in tumor invasion. Enzyme Protein
1996, 49:38-58
32. Forsberg E, Hirsch E, Frohlich L, Meyer M, Ekblom P, Aszodi A,
Werner S, Fassler R: Skin wounds and severed nerves heal nor-
mally in mice lacking tenascin-C. Proc Natl Acad Sci USA 1996,
93:6594-9
33. Mackie E, Tucker R: The tenascin-C knockout revisited. J Cell Sci
1999, 112:3847-53
34. Zlotnik A, Morales J, Hedrick J: Recent advances in chemokines
and chemokine receptors. Crit Rev Immunol 1999, 19:1-47
35. Gillitzer R, Goebeler M: Chemokines in cutaneous wound heal-
ing. J Leukoc Biol 2001, 69:513-521
36. Martins-Green M, Tilley C, Schwarz R, Hatier C, Bissell M: Wound-
factor-induced and cell cycle phase-dependent expression of
9E3/CEF4, the avian gro gene. Cell Regul 1991, 2:739-752
37. Feugate JE, Li QJ, Martins-Green M: Stimulation of myofibroblast
differentiation by human CXC chemokines. Mol. Biol. of the Cell.
2001, Suppl. 12:2312
38. Rennekampff H, Hansbrough J, Kiessig V, Doré C, Sticherling M,
Schröder J: Bioactive interleukin-8 is expressed in wounds and
enhances wound healing. J Surg Res 2000, 93:41-54
39. Koch A, Polverini P, Kunkel S, Harlow L, DiPietro L, Elner V, Elner S,
Strieter R: Interleukin-8 as a macrophage-derived mediator of
angiogenesis. Science 1992, 258:1798-1801
40. Strieter R, Kunkel S, Elner V, Martonyi C, Koch A, Polverini P, Elner
S: Interleukin-8. A corneal factor that induces neovasculari-
zation. Am J Pathol 1992, 141:1279-1284
41. Li Q-J, Martins-Green M: Molecular mechanisms by which IL-8
stimulates initiation of angiogenesis. Mol. Biol. of the Cell. 2001,
Suppl. 12:1466
42. Matsuda A, Yoshiki A, Tagawa Y, Matsuda H, Kusakabe M: Corneal
wound healing in tenascin knockout mouse. Invest Ophthalmol
Vis Sci 1999, 40:1071-1080
43. Yoshida T, Yoshimura E, Numata H, Sakakura Y, Sakakura T: Involve-
ment of tenascin-C in proliferation and migration of larynge-
al carcinoma cells. Virchows Arch 1999, 435:496-500
44. Wallner K, Sharifi B, Shah P, Noguchi S, DeLeon H, Wilcox J: Adven-
titial remodeling after angioplasty is associated with expres-
sion of tenascin mRNA by adventitial myofibroblasts. J Am Coll
Cardiol 2001, 37:655-661
45. Lloyd C, Minto A, Dorf M, Proudfoot A, Wells T, Salant D, Gutierrez-
Ramos J: RANTES and monocyte chemoattractant protein-1
(MCP-1) play an important role I the inflammatory phase of
crescentic nephritis, but only MCP-1 is involved in crescent
formation and interstitial fibrosis. J Exp Med 1997, 185:1371-
1380
46. Unemori E, Amento E, Bauer E, Horuk R: Melanoma growth-stim-
ulatory activity/GRO decreases collagen expression by hu-
man fibroblasts. J Biol Chem 1993, 268:1338-1342
47. Magnusson M, Mosher D: Fibronectin: structure, assembly, and
cardiovascular implications. Arterioscler Thromb Vasc Biol 1998,
18:1363-70
48. Doucet J, Trifaro J: A discontinous and highly porous sodium
dodecyl sulfate-polyacrylamide slab gel system of high reso-
lution. Anal Biochem 1988, 168:265-271
49. Paech and Christiansen:  In Cell biology: a laboratory handbook.  (Edited
by: J Celis) San Diego: Academic Press 1994, 3:264-271
50. Tucker R: Abnormal neural crest cell migration after the in
vivo knockdown of tenascin-C expression with morpholino
antisense oligonucleotides. Dev Dyn 2001, 222:115-119
51. Vaingankar S, Martins-Green M: Thrombin activation of the 9E3/
CEF4 chemokine involves tyrosine kinases including c-src
and the epidermal growth factor receptor. J Biol Chem 1998,
273:5226-5234
Publish with BioMed Central  and  every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.comPage 15 of 15
(page number not for citation purposes)
